Clinical Trial Update: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ixazomib citrate with rituximab in indolent B-cell non-Hodgkin lymphoma has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Lymphoplasmacytic Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• NINLARO (ixazomib)
• Rituxan (rituximab)

Snippet

Sponsor: University of Washington | Conditions: Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-05